Medication info
Duotellmi Plus Tablet 40/5/10 mg (Telmisartan, Amlodipine, Rosuvastatin)

Duotellmi Plus Tablet 40/5/10 mg (Telmisartan, Amlodipine, Rosuvastatin)

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›40mg / 1 tabletAmlodipine Besylate›6.935mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Korea Huytex Pharmaceutical Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202500394 · Approved 2025.02.24 · Insurance code 649106100

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, and prevention of atherosclerosis progression and cardiovascular disease risk
Who takes it
Adults
Adult dose
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking a telmisartan/amlodipine combination and rosuvastatin as separate products, they may be switched to this medicine (a combination product containing the same amount of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended to adjust the dose using the individual ingredients (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual ingredients as described below, switching directly to the telmisartan/amlodipine combination may be considered. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is required for patients with mild or moderate renal impairment. For patients with severe renal impairment, it is recommended to initiate treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In patients 75 years of age or older, amlodipine clearance is reduced; therefore, treatment should be initiated at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 mg daily. 2. Elderly patients: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: Systemic exposure to rosuvastatin was not increased in patients with a Child-Pugh score of 7 or less, but was increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of rosuvastatin 40 mg is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/10mg and rosuvastatin 20mg, rosuvastatin Cmax increased by approximately 2.4-fold and AUC by approximately 1.3-fold in the presence of telmisartan/amlodipine. Therefore, when administering this medicine, assess the potential risk due to the increase in rosuvastatin Cmax and monitor patients closely.

Ingredients

Manufacturer
Korea Huytex Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, and prevention of atherosclerosis progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • familial heterozygous hypercholesterolemia
  • combined hyperlipidemia
  • familial homozygous hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used for patients who need to take telmisartan/amlodipine combination and rosuvastatin simultaneously. The telmisartan/amlodipine combination helps effectively lower blood pressure in patients with essential hypertension who have difficulty controlling blood pressure with monotherapy. Rosuvastatin reduces cholesterol levels and improves vascular health in patients with hypercholesterolemia and hyperlipidemia that are not controlled by dietary measures. Additionally, it helps reduce the risk of cardiovascular diseases, contributing to lowering the risk of stroke, myocardial infarction, and arterial revascularization. Therefore, this drug combination is used to manage hypertension and hyperlipidemia simultaneously, improving cardiovascular health.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking a telmisartan/amlodipine combination and rosuvastatin as separate products, they may be switched to this medicine (a combination product containing the same amount of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended to adjust the dose using the individual ingredients (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual ingredients as described below, switching directly to the telmisartan/amlodipine combination may be considered. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is required for patients with mild or moderate renal impairment. For patients with severe renal impairment, it is recommended to initiate treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In patients 75 years of age or older, amlodipine clearance is reduced; therefore, treatment should be initiated at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 mg daily. 2. Elderly patients: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: Systemic exposure to rosuvastatin was not increased in patients with a Child-Pugh score of 7 or less, but was increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of rosuvastatin 40 mg is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/10mg and rosuvastatin 20mg, rosuvastatin Cmax increased by approximately 2.4-fold and AUC by approximately 1.3-fold in the presence of telmisartan/amlodipine. Therefore, when administering this medicine, assess the potential risk due to the increase in rosuvastatin Cmax and monitor patients closely.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. Patients with allergies to this drug, similar drugs, or certain hereditary diseases, as well as those with severe liver or kidney disease, should not take it. While used for the treatment of hypertension and dyslipidemia, this drug should be administered under careful observation by a physician in patients with severe hypotension, the elderly, or those with hyperkalemia. Muscle pain, muscle disease, liver function abnormalities, and other side effects may occur, so if muscle pain or weakness symptoms appear during treatment, it is essential to consult a healthcare professional immediately. Regular blood tests to check muscle enzyme levels and liver function before and during medication are recommended. This medication may interact with other specific drugs, so if there are other medications being taken, it is crucial to inform the healthcare professional. It is advisable not to take this medication during breastfeeding, and if it must be taken, breastfeeding should be discontinued. Safety and efficacy have not been established in children under 18 years, so it is not recommended. In case of overdose, hypotension or cardiac function abnormalities may occur, requiring immediate treatment at a medical facility. This medication should be kept out of reach of children and care should be taken not to transfer it to another container.

Side effects

  • Viral upper respiratory infection
  • dyspnea
  • rectal bleeding
  • dyspepsia
  • atopic dermatitis
  • peripheral edema
  • chronic gastritis
  • various gastrointestinal disorders
  • hiatal hernia
  • dysuria
Show 163 more
  • rhinitis
  • oropharyngeal discomfort
  • lung disease
  • unspecified intestinal disease
  • benign gastrointestinal neoplasm
  • hemorrhoids
  • skeletal pain
  • osteoporosis
  • sensory loss
  • movement disorders
  • atherosclerosis
  • frequent urination
  • tinnitus
  • hearing loss
  • halitosis
  • fatty liver
  • upper respiratory infection
  • low back pain
  • sinusitis
  • diarrhea
  • pharyngitis
  • erectile dysfunction
  • increased sweating
  • flushing
  • allergy
  • fever
  • leg pain
  • fatigue
  • palpitations
  • dependent edema
  • angina
  • rapid pulse
  • leg edema
  • abnormal ECG
  • insomnia
  • drowsiness
  • migraine
  • dizziness
  • sensory disturbances
  • involuntary muscle contractions
  • constipation
  • vomiting
  • dry mouth
  • hemorrhoids
  • gastroenteritis
  • enteritis
  • gastroesophageal reflux
  • toothache
  • nonspecific gastrointestinal disease
  • gout
  • hypercholesterolemia
  • diabetes
  • arthritis
  • joint pain
  • leg numbness
  • anxiety
  • depression
  • neuroticism
  • infection
  • fungal infection
  • abscess
  • otitis media
  • asthma
  • bronchitis
  • nosebleed
  • dermatitis
  • rash
  • eczema
  • itching
  • vascular edema
  • polymorphic erythema
  • vasculitis
  • peripheral neuropathy
  • tremors
  • loss of appetite
  • dysphagia
  • pancreatitis
  • gingival hyperplasia
  • myasthenia
  • burning sensation
  • fatigue
  • rigidity
  • weight gain
  • weight loss
  • nocturia
  • dry mouth
  • hyperglycemia
  • thirst
  • leukopenia
  • purpura
  • thrombocytopenia
  • heart failure
  • irregular pulse
  • extrasystole
  • skin discoloration
  • dry skin
  • hair loss
  • muscle weakness
  • isolated contraction
  • dyskinesia
  • excessive muscle tone
  • cold moist skin
  • apathy
  • restlessness
  • amnesia
  • gastritis
  • increased appetite
  • loose stools
  • rhinitis
  • urination disorder
  • polyuria
  • abnormal olfaction
  • taste disturbance
  • abnormal eye accommodation
  • dry eyes
  • gynecomastia
  • jaundice
  • elevated liver enzyme levels
  • leukopenia
  • confusion
  • exfoliative dermatitis
  • Stevens-Johnson syndrome
  • photosensitivity reaction
  • toxic epidermal necrolysis
  • headache
  • myalgia
  • myopathy
  • rhabdomyolysis
  • myasthenia
  • constipation
  • nausea
  • abdominal pain
  • itching
  • skeletal muscle pain
  • neck pain
  • nasopharyngitis
  • upper abdominal discomfort
  • upper abdominal pain
  • positional vertigo
  • vascular edema
  • thrombocytopenia
  • increased serum creatinine
  • acute renal failure
  • oliguria
  • visual disturbances
  • conjunctivitis
  • diplopia
  • ocular pain
  • ear pain
  • syncope
  • generalized pain
  • muscle cramps
  • gout
  • erectile dysfunction
  • sensory loss
  • movement disorders
  • thrombocytopenia
  • vascular edema
  • vasculitis
  • thrombocytopenia
  • increased serum creatinine
  • acute renal failure
  • oliguria

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a container that does not allow light to enter, as it may be sensitive to light. Additionally, it is best to store the medicine at room temperature between 1 and 30 degrees Celsius. Proper storage helps maintain the medicine's effectiveness.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.